A humanized monoclonal IgG1 antibody that targets T cell interactions in psoriasis.
Antibody to CD-11a, the alpha sub-unit of LFA.
Causes significant improvement in the management of moderate to severe psoriasis.
Most common adverse reaction flulike symptoms.
Small number of treated patients develop thrombocytopenia.
Weekly injectable treatment for psoriasis associated with increases risk of serious and life threatening infections.
Confirmed cases of progressive multifocal leukoencephalopathy (PML) have been rarely reported.